EIDX

Eidos Therapeutics Inc

A maker of medicines for a rare disease called transthyretin amyloidosis, where a liver protein misfolds and builds up in the heart and nerves. Its lead drug, acoramidis (once called AG10), is an oral pill designed to copy a natural "rescue mutation" that luckily protects some people from the illness. Founded around 2016 as a subsidiary of BridgeBio Pharma, the company takes its name from the Greek word eidos, meaning "form" — fitting for a firm built around how proteins are shaped.

No Schedule 13D or 13G filings recorded.